Niche Focus Target ophthalmology and neurology adjacent markets where sustained local drug exposure in the ear demonstrates potential for broader otology indications, presenting cross-sell opportunities into Ménière’s disease, hearing loss, and tinnitus treatment pipelines.

Strategic Partnerships Leverage Otonomy’s history of collaborations (e.g., AGTC) to pursue co-development or licensing deals for AAV-based gene therapies or other otology indications, expanding offerings without bearing full development risk.

Clinical Milestones Monitor late-stage trial outcomes and higher-dose evaluations for OTO-413 and OTO-313; identify partners or customers interested in risk-sharing agreements or early-access programs if future data show signal recovery.

Local Delivery Advantage Position as a supplier or collaborator for sustained/local delivery technologies and pipelines that reduce systemic exposure, appealing to pharma seeking patient-friendly, single-administration therapies for ear conditions.

Market Entry Readiness Offer regulatory and translational support packages to potential acquirers or co-developers, highlighting their early internal programs, existing patent estate on ear drug delivery, and U.S. market launch history with OTIPRIO as proof of commercial capability.